Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
NBIX Key Statistics
Stock Snapshot
As of today, Neurocrine(NBIX) shares are valued at $152.50. The company's market cap stands at 15.12B, with a P/E ratio of 34.28.
During the trading session on 2025-11-27, Neurocrine(NBIX) shares reached a daily high of $153.54 and a low of $146.00. At a current price of $152.50, the stock is +4.5% higher than the low and still -0.7% under the high.
Trading volume for Neurocrine(NBIX) stock has reached 1.73M, versus its average volume of 1.01M.
The stock's 52-week range extends from a low of $84.23 to a high of $157.67.
The stock's 52-week range extends from a low of $84.23 to a high of $157.67.
NBIX News
Analyst Yigal Nochomovitz from Citi maintained a Buy rating on Neurocrine and keeping the price target at $203.00. TipRanks Black Friday Sale Claim 60% off TipR...
TipRanks Black Friday Sale Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to Tip...
Neurocrine Biosciences recently announced the publication of a comprehensive peer-reviewed review consolidating clinical and pharmacologic data on FDA-approved...
Analyst ratings
90%
of 30 ratingsMore NBIX News
Neurocrine Biosciences (NBIX) recently reported results from its Phase 2 trial of NBI-1070770 for major depressive disorder. The investigational drug did not me...